Abstract��OBJECTIVE To introduce the research progress of dosage regimen of piperacillin/tazobactam and its rational offer reference for clinical use.METHODS The domestic and oversea pertinent articles were searched, analyzed and summarized, and the difference between prolonged infusion or continuous infusion and traditional infusionin pharmacodynamics and clinical trials were compared. RESULTS The optimized dosage regimen could achieve higher pharmacodynamics goals, with clinical efficacy and bacterial clearance not inferior to the traditional dosage regimen.CONCLUSION The prolonged or continuous infusion strategy should be recommended for piperacillin/tazobactam in the clinic.
����Ө, ������, ��һ, ������. ��������/�����̹�Ż���ҩ�������о���״���ٴ�����Ӧ��[J]. �й�ҩѧ��־, 2016, 51(18): 1608-1614.
WANG Yu-ying, WANG Xiao-xuan, LIU Yi, FENG Wan-yu. Outcomes and Rational Clinical Use of Extended or Continuous Versus Intermittent Infusion of Piperacillin/Tazobactam. Chinese Pharmaceutical Journal, 2016, 51(18): 1608-1614.
HAWKEY P M,JONES A M. The changing epidemiology of resistance [J].Antimicrob Chemother,2009,64(1):3-10.
[2]
JOSEPH S S,JOHN E M,JOHN S B,et al. Diagnosis and management of complicated intra-abdominal infection in adults and children:guidelines by the surgical infection society and the infectious diseases Society of America[J].Clin Infect Dis,2010,50(2):133-164.
[3]
Diagnosis and management of community-and hospital-acquired pneumonia in adults[J/OL].NICE Clinical Guideline 191,2014,guidance. nice. org. uk/cg191.
[4]
KIM A,SUTHERLAND C A,KUTI J L,et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections:prolonged or continuous infusion?[J].Pharmacotherapy,2007,27(11):1490-1497.
[5]
BUCK C,BERTRAM N,ACKERMANN,et al. Pharmacokinetics of piperacillin-tazobactam:intermittentdosing vers us continuous infusion[J].Int J Antimicrob Agents,2005,25(1):62-67.
[6]
GEORGES B,CONIL J M,COUGOT P,et al. Cefepime in critically illpatients:continuous infusion vs. an intermittent dosing regimen[J].Int J Clin Pharmacol Ther,2005,43(8):360-369.
[7]
RAFATI M R,ROUINI M R,MOJTAHEDZADEH M,et al. Clinicalefficacyof continuous infusion of piperacillin compared with intermittentdosing in septic critically ill patients[J].Int J Antimicrob Agents,2006,28(2):122-127.
[8]
AMOBROSE P G,BHAVNANI S M,RUBINO C M,et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy:it's not just for mice anymore[J].Clin Infect Dis,2007,44(1):79-86.
[9]
LODISE T P,LOMAESTRO B M,DRUSANO G L. Application of antimicrobial pharmacodynamic concepts into clinical practice:focus on beta-lactam antibiotics:insights from the Society of Infectious Diseases Pharmacists[J].Pharmacotherapy,2006,26 (9):1320-1332.
[10]
YE L Q,CAI T. Application of pharmacokinetics / pharmacodynamics model in optimization of antibiotic administration by Monte Carlo[J].Mod Pract Med(�ִ�ʵ��ҽѧ),2009,21(1):5-6.
[11]
DERYKE C A,KUTI J L,NICOLAU D P. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa,Acinetobacter baumannii,Escherichia coli,and Klebsiella species collected from United States intensive care units in 2004[J].Pharmacotherapy,2007,27(3):333-342.
[12]
ROBERTS J A,KIRKPATRICK C M,ROBERTS M S,et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis[J].Int J Antimicrob Agents,2010,35(2):156-163.
[13]
CAI T,YE L Q. Pharmacodynamics of prolonged and continuous infusion regimens of three ��-lactam antimicrobial agents against extended-spectrum ��-lactamases producing bacteria[J].Chin J Nosocomiol(�л�ҽԺ��Ⱦѧ��־),2010,20(14):2110-2113.
[14]
SHEA K M,CHEATHAM S C,WACK M F,et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin /tazobactam administered by prolonged infusion inhospitalized patients[J].Int J Antimicrob Agents,2009,34(5):429-433.
[15]
LODISE T P,LOMAESTRO B,DRUSANO G L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection:clinical implications ofan extended-infusion dosing strategy[J].Clin Infect Dis,2007,44(3):357-363.
[16]
GUILHERME H F,LEANDRO C,RODRIGO S M,et al. Pharmacokinetic/pharmacodynamic target attainmentof intravenous ��-lactam regimens against Gram-negativebacteria isolated in a Brazilian teaching hospital[J].Rev Soc Bras Med Trop,2015,48(5):539-545.
[17]
YE L Q,CAI T.Use of Monte Carlo simulation to optimize dosing regimens for Piperacillin-tazobactam [J].Chin J Clin Pharmacol Ther(�й��ٴ�ҩ��ѧ������ѧ),2010,15(8):901-905.
[18]
HUI Y,ZHANG C H,ZHOU Q Y,et al. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam:a systematic review and Meta-analysis[J].PLoS One,2015,10(1):1-13.
[19]
MATTHEW E F,GIANNOULA S T,KAZUROLKAWA,et al. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam:a systematic review and Meta-analysis[J].Clin Pract,2015,56(2):272-282.
[20]
ZHANG X,ZHAI S D. Clinical outcomes with alternative dosing strategies for ��-lactam antimicrobial:a Meta-analysis[C].Chinese Pharmacological Society,The Third Academic Annual Conference on therapeutic drug monitoring,Beijing,2015:22.
[21]
ZHANG X M,HONG B,YE J H. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with respiratory tract infection[J].Chin J Clin Pharmacol Ther(�й��ٴ�ҩ��ѧ������ѧ),2015,20(6):677-681.
[22]
HE C,SHEN L Y,DU Q S,et al. Clinical study on the treatment of Pseudomonas aeruginosa infection with piperacillin tazobactam according to PD/PK theoretical guidance[J].Mod Prev Med(�ٴ�������ҩ),2014,7(10A):41-42.
[23]
JOEL M D,JASON A,ROBERTS J S, et al. Continuous infusion of beta-lactam antibioticsin severe sepsis:a multicenter double-blind, randomized controlled trial[J].Clin Infect Dis,2013,56(2):236-244.
[24]
LV Y, YAN Z,WANG D H,et al. Treatment study of hospital acquired pneumonia by optimizing dosing regimen of piperaeillin/tazobactam:prolonged vs regular infusion[J].Chin Crit Care Med(�л�Σ�ز�����ҽѧ),2013,25(8):479-483.
[25]
LEE G C,LIOU H, YEE R,et al. Outcomes of extended-infusion piperacillin-tazobactam:a retrospective analysis of critically ill patients[J].Clin Ther,2012,34(12):2297-300.
[26]
GONCALVES P J,OLIVEIRA B S, JANEIRO S,et al. Continuous infusion ofpiperacillin/tazobactam in septic critically ill patients-a multicenter propensity matched analysis[J].PLoS One,2012,7(11):e49845.
[27]
YOST R J,CAPPELLRTTY D M, RECEIPT STUDY GRA, et al. The retrospective cohort of infusion piperacillin/tazobactam (RECEIPT) study:a multicenter study[J].Pharmacotherapy,2011,31(8):767-775.
[28]
YE L Q, CAI T. Clinical study of extending administration time of piperacillin/tazobactam intreatment of Gram-negative bacteria infection [J].Chin J Nosocomiol(�й�ҽԺ��Ⱦѧ��־),2011,21(16):3476-3479.
[29]
ROBERTS J A, KIRKPATRICK C M. Pharmacokinetics of piperacillin-tazobactam:intermittent dosing versus continuous infusion[J].Int J Antimicrob Agent,2005,25(1):62-67.
[30]
LI Z Q,ZHANG Y G,WANG C Y,et al. Clinical efficacy of continuous infusion of piperacillin/tazobactam in severe pneumonia patients:a randomized controlled clinical trial[J].Mod Prev Med(�ִ�Ԥ��ҽѧ),2010,37(15):2949-2951.
[31]
LORENTE L, JIMENEZ A, MARTIN M M,et al. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion[J].Int J Antimicrob Agent,2009,33(5):464-468.
[32]
PATEL G W, PATEL N,LAT A,et al. Outcomes of extended infusion piperacillin/tazobactam for documented gram-negative infections[J].Diagn Microbiol Infect Dis,2009,64(2):236-240.
[33]
LODISE T P,LOMAESTRO B,DRUSANO G L. Piperacillin- tazobactam for Pseudomonas aeruginosa infection:clinical implications of an extended-infusion dosing strategy[J].Clin Infect Dis,2007,44(3):357-363.
[34]
RAFATI M R,ROUINI M R,MOJTAHEDZADEH M,et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients[J].Int J Antimicrob��Agents,2006,28(2):122-127.
[35]
LAU W K, MERCER D,ITANI K M,et al. Randomized,open-label,comparativestudy of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion fortreatment of hospitalized patients with complicated intra-abdominal infection[J].Antimicrob Agents Chemother,2006,50(11):3556-3561.
[36]
BUCK C, BERTRAM N, ACKERMANN T,et al. Pharmacokinetics of piperacillin-tazobactam:intermittent dosingversus continuous infusion[J].Int J Antimicrob Agents,2005,25(20):62-67.
[37]
GRANT E M,KUTI J L,NICOLAU D P,et al.Clinical efficacy andpharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital[J].Pharmacotherapy,2002,22(4):471-483.
[38]
XAMPLAS R C,ITOKAZU G S,GLOWACKI R C,et al. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital[J].Am J Health Syst Pharm,2010, 67(8):622-628.
[39]
HEINRICH L S,TOKUMARU S,CLARK N M,et al. Development and implementation of a piperacillin-tazobactam extended infusion guideline [J].Pharm Pract,2011,24(6):571-576.
[40]
FLOREA N R,KOTAPATI S,KUTI J L,et al. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam:a time-motion study[J].Am J Health Syst Pharm,2003,60(22):2321-2327.
[41]
OBRINK-HANSEN K,JENSEN-FANGEL S,BROCK B,et al. Piperacillin/tazobactam continuous infusion at 12G/1.5G per day in CF patients results in targetplasma-concentrations[J].J Cyst Fibros,2016,16(2):e13-e14.
2016, Vol. 51 
